1. Introduction {#sec1}
===============

Community-acquired pneumonia (CAP) is pneumonia that is not acquired in a hospital or a long-term care facility within the past 14 days \[[@B1]\]. In the United States, the total cost of health care for CAP was \$8.4 billion in 2001, and 5.6 million cases of CAP occur each year \[[@B1], [@B2]\]. The combination of pneumonia and influenza is the eighth leading cause of death in the United States \[[@B3]\]. In Taiwan, pneumonia was the fourth leading cause of death in 2012, according to the statistics of the Ministry of Health and Welfare \[[@B4]\]. Therefore, diagnosing and treating CAP early is vital to reducing morbidity and mortality \[[@B3]\]. Clinically, the leukocyte (WBC) count and C-reactive protein (CRP) level are used to monitor pneumonia severity \[[@B5]\]. However, several studies have questioned using the WBC count and CRP to predict the prognosis of CAP \[[@B6], [@B7]\]. The specificity and sensitivity of these diagnostic markers are not good enough, especially for predicting CAP severity. Therefore, the purpose of this study was to investigate the biological markers for early diagnosis and detect the severity of CAP.

The Pneumonia Severity Index (PSI) is used worldwide, including Taiwan. Physicians determine the disposition of CAP patients by evaluating the severity of CAP according to the PSI. The CURB-65 score, which is the sum of 5 risk factors (i.e., confusion, urea, respiratory rate, blood pressure, and an age of 65 years or older), measures the severity of CAP \[[@B8], [@B9]\]. Patients scoring 0, 1, and 2 according to CURB-65 have a 30-day mortality of 0.7%, 3.2%, and 3%, respectively. One study reported that the PSI and CURB-65 scoring systems were similar in predicting the 28-day in-hospital mortality of the patients with severe sepsis and CAP \[[@B10]\].

SDF-1, also called CXCL12, is a chemotactic cytokine belonging to the large family of CXC chemokines. SDF-1 is related to a different chemokine-chemokine receptor axis and regulates the movement of neutrophils, monocytes, T-lymphocytes, and basophils. SDF-1 also induces cell migration, cell adhesion, neutrophil activation, and inflammation \[[@B11]\]. Another study reported that the CXCR4/SDF-1 axis plays a crucial role in the recruitment of neutrophils to the lung during acute lung injury, and this cytokine axis was noted in the reparative response to lung injury \[[@B12]\]. SDF-1 signaling during sepsis is vital for neutrophil bone marrow mobilization and host survival \[[@B13]\]. Overexpression of SDF-1 has been reported to be associated with inflammatory diseases, such as rheumatoid arthritis (RA), acute myocardial infarction, pelvic inflammatory disease (PID), and pathogenesis of atherosclerosis \[[@B14]--[@B16]\] as well. Furthermore, neutrophils and T-lymphocytes are abundant in the inflammatory lesions of patients with pneumonia and a high neutrophil cell count is found in patient\'s blood \[[@B5]\]. Thus, we hypothesized that the expression of SDF-1 protein is associated with CAP. Although several functions of SDF-1 have been reported, no study has investigated the prognostic value of SDF-1 in a cohort of patients with CAP or proved the association between the severity of CAP and SDF-1. In this study, we measured the plasma levels of the SDF-1 protein in a group of patients with CAP and in healthy control participants to evaluate whether SDF-1 is a useful biochemical marker to differentiate between healthy people and patients with pulmonary infectious disease.

2. Materials and Methods {#sec2}
========================

2.1. Participants and Diagnosis {#sec2.1}
-------------------------------

This study enrolled 121 people (61 CAP patients and 60 healthy controls) from February 2009 to December 2009 at Chung Shan Medical University, Taichung, Taiwan. For a control group, who visited the Department of Family and Community Medicine for health examination in Chung Shan Medical University Hospital, were selected as healthy controls. This study was approved by the Chung Shan Medical University Hospital Institutional Review Board. Demographic characteristics, comorbidities, symptoms and signs of pneumonia, laboratory results, and the previous antibiotic treatments of each patient were recorded upon admission. The guidelines of the Infectious Diseases Society of America/American Thoracic Society were used as diagnostic criteria \[[@B17]\]. The criteria for CAP diagnosis were a typical infiltration change on chest X-ray films within 1 day of symptom occurrence and at least one clinical manifestation, such as cough, yellow and thick sputum, or high fever (\>37.8°C), or at least 2 minor criteria, including tachypnea, dyspnea, pleural pain, chest pain, confusion or disorientation, lung consolidation, or WBC counts \> 12000 cells/*μ*L. Exclusion criteria were outpatient status, transfer from another hospital or hospital admission within the previous 3 weeks, the presence of other acute conditions such as pulmonary edema, pulmonary embolism, or malignancy appearing during the follow-up period, pneumonia caused by tuberculosis or malignancy, and severe immunocompromisations, including severe neutropenia (WBC count lower than 1.0 × 10^9^ cells/L), organ or bone marrow transplant, and HIV infection. Moreover, intake of anti-inflammatory drugs like corticosteroids was also excluded. The pneumonia severity indices were assessed using the PSI, Acute Physiology and Chronic Health Evaluation II (APACHE II), and CURB-65 tests \[[@B18]--[@B20]\].

2.2. Blood Specimen Collection {#sec2.2}
------------------------------

The blood samples from all patients with CAP were obtained to test the WBC and neutrophil cell counts, CRP concentration, and plasma concentration of SDF-1 before and after antibiotic treatment. Blood samples of the control group were also collected and tested. The samples were placed in tubes containing EDTA, and centrifugation was immediately performed. The samples were stored at −80°C. Patients with CAP received treatment with antibiotics such as cefuroxime, ceftizoxime, and clarithromycin according to their condition. [Table 1](#tab1){ref-type="table"} presents a summary of clinical data and the demographics of the patients and controls.

2.3. Measurement of the Plasma SDF-1 Level Using an Enzyme-Linked Immunosorbent Assay {#sec2.3}
-------------------------------------------------------------------------------------

An enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma concentrations of SDF-1 in all blood samples (Quidel Corporation, San Diego, USA). Each plasma sample (100 *μ*L) was directly transferred to the microtest strip wells of the ELISA plate and subsequently incubated for 1 hour at room temperature. After 4 washing steps, the detection antibody was added, and the reaction system was incubated for 1 hour at room temperature. Antibody binding was detected using streptavidin-conjugated horseradish peroxidase and developed using a substrate solution. The reaction was then stopped, and the optical density was determined using a microplate reader set at 450 nm. Soluble SDF-1 concentrations were quantitated according to a calibration curve using a human SDF-1 standard. Each plasma sample was assayed according to the manufacturer\'s instructions, and the values were within the linear portion of the standard curve.

2.4. Statistical Analysis {#sec2.4}
-------------------------

SPSS 15.0 statistics software (SPSS Inc., Chicago, IL) was used to perform statistical analysis. All continuous variables were expressed as mean ± SD. The Mann-Whitney *U* test was used to compare the differences between untreated patients and healthy controls in continuous variables that did not follow a parametric distribution. The Wilcoxon signed-rank test was used to compare the differences in categorical variables between the untreated and treated patients. A Pearson correlation coefficient assessed the association of SDF-1 levels relative to the laboratory variables of patients with CAP. We then plotted receiver-operating characteristic curves (ROCs) to select the cutoff levels of plasma SDF-1 to distinguish patients with pneumonia from normal individuals. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated. Statistical significance was defined as *P* \< 0.05 in 2-tailed tests.

3. Results {#sec3}
==========

A summary of the demographic and clinical characteristics of the participants is presented in [Table 1](#tab1){ref-type="table"}. The analysis in this study was based on a sample of 121 people. The age and sex of the participants did not significantly differ between the CAP group and the control group. According to the PSI, 39, 18, and 4 patients with CAP were classified as low risk, moderate risk, and high risk, respectively. According to CURB-65, 26, 17, and 18 patients were assigned scores 0, 1, and 2, respectively. In addition, 48 and 13 patients received APACHE II scores \< 15 and ≥15, respectively.

[Figure 1(a)](#fig1){ref-type="fig"} shows the SDF-1 expression of the CAP patients and controls. A significantly increased SDF-1 level (*P* \< 0.001) was observed in the plasma of patients with CAP before receiving treatment (2949 ± 1629 ng/mL) compared with healthy controls (1927 ± 625 ng/mL) and significantly decreased (*P* \< 0.001) after treatment (2223 ± 1138 ng/mL). WBC, neutrophil counts, and CRP levels were significantly elevated in patients with CAP before they received treatment compared with the healthy controls (*P* \< 0.001, [Table 1](#tab1){ref-type="table"}) and patients with CAP after they received treatment (*P* \< 0.001, [Table 1](#tab1){ref-type="table"}). The WBC counts of the CAP patients before antibiotic treatment were higher than those of the controls (median 10890 versus 5860 cells/mm^3^; *P* = 0.001) ([Figure 1(b)](#fig1){ref-type="fig"}). The neutrophil counts of the CAP patients before antibiotic treatment (median 8673 versus 3530 cells/mm^3^; *P* = 0.001) were higher than those of the controls. CRP levels among CAP patients were higher than those of the controls before antibiotic treatment (median 86 versus 3 mg/L; *P* = 0.001) ([Figure 1(c)](#fig1){ref-type="fig"}). In addition, CRP levels (before antibiotic treatment: median 86 mg/L, after antibiotic treatment: median 9 mg/L; *P* = 0.001), WBC counts (before antibiotic treatment: median 10890 cells/mm^3^, after antibiotic treatment: median 8450 cells/mm^3^; *P* = 0.001), and neutrophil counts (before antibiotic treatment: median 8673 cells/mm^3^, after antibiotic treatment: median 5484 cells/mm^3^; *P* = 0.001) of patients with CAP were significantly lower after antibiotic treatment than before treatment.

The cutoff levels of plasma SDF-1 and CRP were selected as 2208 ng/mL and 15.3 mg/L, respectively, according to operating characteristics curve (ROC) analysis to distinguish the patients with pneumonia from the control groups. The sensitivities of plasma SDF-1 and CRP were 63.9% and 95.1%, and the specificities were 83.3% and 96.6%, respectively. The positive predictive values of plasma SDF-1 and CRP were 79.6% and 96.6%, and the negative predictive values were 69.4% and 95.1%, respectively. For exploring the potential combination of CRP and SDF-1 in prognosticating CAP, a classification tree obtained by classification and regression tree (CART) analysis was shown in [Figure 2](#fig2){ref-type="fig"}.

[Table 2](#tab2){ref-type="table"} illustrates the association of the WBC count and CRP and SDF-1 levels with the PSI, CURB-65, and APACHE II scores of the CAP patients before antibiotic treatment. Neither a significant association nor a significant difference was observed between the WBC count and CRP level and the PSI (*r* = 0.005, *P* = 0.972, and *n* = 61; *r* = −0.046, *P* = 0.726, and *n* = 61), CURB-65 (*r* = 0.054, *P* = 0.677, and *n* = 61; *r* = −0.040, *P* = 0.758, and *n* = 61), and APACHE II scores (*r* = 0.063, *P* = 0.063, and *n* = 61; *r* = 0.032, *P* = 0.804, and *n* = 61). Additionally, we also found that SDF-1 levels did not exhibit a significant association with WBC, neutrophils, lymphocytes, monocytes, platelets, CRP, and the length of hospital stay ([Table 2](#tab2){ref-type="table"}). By contrast, the SDF-1 levels of the CAP patients before receiving treatment were significantly correlated with the PSI, CURB-65, and APACHE II scores (*r* = 0.389, *P* = 0.002, and *n* = 61; *r* = 0.449, *P* \< 0.001, and *n* = 61; and *r* = 0.363, *P* = 0.004, and *n* = 61, resp.). Moreover, significant differences in SDF-1 levels were observed between Class I and Class IV (*P* = 0.013), Class I and Class V (*P* = 0.002), Class II and Class IV (*P* = 0.015), and Class II and Class V (*P* = 0.009) patients ([Figure 3(a)](#fig3){ref-type="fig"}). Moreover, significantly different SDF-1 levels were observed in patients who were classified as low risk and those who were classified as medium risk (*P* = 0.025), as well as between patients who were classified as low risk and those who were classified as high risk, according to PSI scores (*P* = 0.046) ([Figure 3(b)](#fig3){ref-type="fig"}). [Figure 4](#fig4){ref-type="fig"} shows that the SDF-1 levels significantly differed between patients who scored 0 and those who scored 2 (*P* \< 0.001) on CURB-65. Furthermore, the SDF-1 levels significantly differed between patients with an APACHE II score \< 15 and those with a score ≥ 15 (*P* = 0.02) ([Figure 5](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

This study showed significant differences in CRP concentrations, WBC counts, and neutrophils between patients with CAP and healthy controls. Significant differences in CRP concentrations, WBC, and neutrophil counts between patients with CAP before and after antibiotic therapy were also noted. WBC, neutrophil counts, CRP concentrations, and other biomarkers such as procalcitonin (PCT) and proadrenomedullin (pro-ADM) are used to predict the severity and prognosis of CAP \[[@B21]--[@B23]\]. However, the potential roles of these diagnostic markers for predicting CAP severity were still controversial \[[@B7], [@B24]--[@B26]\]. In this study, there was no significant association between CRP and any of PSI, Curb-65, or APACHE II scores. Moreover, the CRP level in CAP was affected by a different infection source. One study indicated that patients with*Legionella pneumophila* pneumonia had higher CRP levels than did those with pneumonia of any other etiology, independent of the severity of infection \[[@B27]\]. Elevated CRP levels were noted when patients experienced chronic inflammation caused by conditions such as cardiovascular disease, metabolic syndrome, and colorectal cancer \[[@B28]\]. The baseline CRP levels of patients are higher when patients are experiencing chronic inflammation. This may be one of the reasons that CRP levels are less related to PSI and CURB-65 scores than SDF-1 levels are. Patients with CAP exhibited markedly elevated CRP and SDF-1 levels, but only SDF-1 was correlated with the severity of CAP in our study, indicating that CRP levels are sensitive to pulmonary infection but are not as closely correlated with CAP severity as SDF-1. SDF-1 has been associated with inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis (RA), subacromial bursitis, and encephalitis \[[@B29]--[@B33]\]. Burgoyne et al. observed that the SDF-1 levels of synovial tissues were increased in RA patients who experienced relapses compared with RA patients who experienced remissions \[[@B15]\]. Leone et al. observed that the serum SDF-1 concentration was higher in patients with acute myocardial infarction than in healthy controls \[[@B16]\]. However, the relationship between SDF-1 levels and the therapeutic effect of CAP is unclear. Our results indicated a significant difference between the SDF-1 levels of patients with CAP and those of healthy controls as well as between the SDF-1 levels of patients with CAP before antibiotic treatment and after antibiotic treatment. In this study, we confirmed that the plasma concentration of SDF-1 is significantly correlated with the therapy effect for CAP patients.

The PSI is commonly used to predict the severity of CAP. The results of our study indicated a significant difference in the SDF-1 levels of patients with CAP compared with those of healthy controls as well as between the SDF-1 levels of patients with CAP before and after antibiotic treatment. We also determined that SDF-1 concentration is associated with the PSI, which is the most common index used to determine whether a patient should be hospitalized and could predict the mortality of patients with CAP. In addition, significantly different SDF-1 levels were observed between patients who were classified as low risk and those who were classified as moderate risk (*P* = 0.025) and between patients who were classified as low risk and those who were classified as high risk according to PSI scores (*P* = 0.046). Patients with CAP who are determined to be at a moderate or high risk according to the PSI should be hospitalized for treatment. According to the PSI, a moderate risk of mortality is 8.2%, and a high risk of mortality is approximately 29.2% \[[@B1]\]. SDF-1 is a convenient diagnostic biomarker for determining whether a patient with CAP should be hospitalized and is a valuable tool that informs physicians of the risk of mortality of patients with CAP. Moreover, a significant difference in SDF-1 levels was observed between patients with APACHE-II scores \< 15 and those with scores ≥ 15 (*P* = 0.02). Our study showed that the plasma concentration of SDF-1 was significantly correlated with CURB-65, APACHE II, and, especially, PSI scores. Therefore, an elevated plasma SDF-1 concentration can be used a marker for the early detection of CAP severity. This is the first demonstration of the association between SDF-1 and CAP severity. The limitation of this study is the deficiency of microbial data. Differences in pathogens may cause differences in the severity of CAP. Therefore, our future studies will focus on the association between SDF-1 and the various microbial pathogens that cause CAP.

In conclusion, plasma SDF-1 may play a role in the clinical assessment of the severity of CAP and can potentially guide the development of treatment methods and predict clinical outcomes. Moreover, an elevated plasma SDF-1 concentration can be used as a biological marker for the early diagnosis of CAP.
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![Levels of plasma (a) stromal-cell-derived factor-1 (SDF-1), (b) WBC counts, and (c) CRP levels in control subjects, and patients with community-acquired pneumonia (CAP) before and after treatment. The plasma SDF-1 level, WBC counts, and CRP levels were significantly elevated in patients with CAP before they received treatment compared to the controls and significantly decreased in CAP patients after having received treatment (*P* \< 0.001).](DM2014-829706.001){#fig1}

![Classification and regression tree (CART) analysis for the control and CAP groups using plasma stromal-cell-derived factor-1 (SDF-1) levels and CRP data.](DM2014-829706.002){#fig2}

![Levels of plasma stromal-cell-derived factor-1 (SDF-1) in Pneumonia Severity Index (PSI) scores in 61 patients with community-acquired pneumonia (CAP). (a) There was a significant different between Class V and Class I and Class II PSI scores. (b) There was a significant difference between high risk and low risk PSI score (*P* \< 0.05).](DM2014-829706.003){#fig3}

![Levels of plasma stromal-cell-derived factor-1 (SDF-1) in CURB-65 scores in 61 patients with community-acquired pneumonia (CAP). There was a significant difference between patients who scored 0 and those who scored 2 (*P* \< 0.001) on CURB-65.](DM2014-829706.004){#fig4}

![Levels of plasma stromal-cell-derived factor-1 (SDF-1) in APACHE II scores in 61 patients with community-acquired pneumonia (CAP). There was a significant difference between patients with an APACHE II score \< 15 and those with a score ≥ 15 (*P* = 0.02).](DM2014-829706.005){#fig5}

###### 

Laboratory data of both controls and patients with community-acquired pneumonia (CAP) before and after they received treatment^a^.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical variable           Controls (*n* = 60)\   Before antibiotic treatment (*n* = 61)\   After antibiotic treatment (*n* = 61)\   *P* value\     *P* value\
                              Median (range)         Median (range)                            Median (range)                           UT/C^b^        UT/T^c^
  --------------------------- ---------------------- ----------------------------------------- ---------------------------------------- -------------- --------------
  Age                         59.4 ± 1.5^d^          59.5 ± 2.6                                                                         *P* = 0.963     

  Gender                                                                                                                                                

   Male                       36 (60%)               37 (60.7%)                                                                         *P* = 0.941     

   Female                     24 (40%)               24 (39.3%)                                                                                         

  CRP (mg/L)                  3 (1--17)              86 (7--274)                               9 (3--113)                               *P* \< 0.001   *P* \< 0.001

  WBCs (cells/mm^3^)          5860 (3110--10190)     10890 (3560--32480)                       8450 (3460--22340)                       *P* \< 0.001   *P* \< 0.001

  Neutrophils (cells/mm^3^)   3530 (1738--6046)      8673 (1032--29686)                        5484 (1518--21155)                       *P* \< 0.001   *P* \< 0.001

  PSI score                                                                                                                                             

   Class I                                           13 (21.3%)                                                                                         

   Class II                                          13 (21.3%)                                                                                         

   Class III                                         13 (21.3%)                                                                                         

   Class IV                                          18 (29.5%)                                                                                         

   Class V                                           4 (6.6%)                                                                                           

  CURB-65 score                                                                                                                                         

   0                                                 26 (42.6%)                                                                                         

   1                                                 17 (27.9%)                                                                                         

   2                                                 18 (29.5%)                                                                                         

  APACHE II score                                                                                                                                       

   \<15                                              48 (78.7%)                                                                                         

   ≥15                                               13 (21.3%)                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRP: C-reactive protein; WBCs: white blood cells; C: controls; UT: patients with CAP before they received antibiotic treatment; T: patients with CAP after they received antibiotic treatment.

^a^ *P* \< 0.05 was considered significant.

^b^The statistical difference was analyzed by the Mann-Whitney *U* test.

^c^The statistical difference was analyzed by the Wilcoxon signed-rank test.

^d^Mean ± SD.

###### 

Association of white blood cells (WBCs), C-reactive protein (CRP), and SDF-1 with clinical pathological features.

  Variable                  WBC (*n* = 61)   CRP (*n* = 61)   SDF-1 (*n* = 61)                    
  ------------------------- ---------------- ---------------- ------------------ ------- -------- ---------
  PSI score                 0.005            0.972            −0.046             0.726   0.389    0.002
  CURB-65 score             0.054            0.677            −0.040             0.758   0.449    \<0.001
  APACHE II score           0.063            0.630            0.032              0.804   0.363    0.004
  Length of hospital stay   −0.044           0.736            0.086              0.183   0.183    0.157
  WBC                       ---              ---              0.130              0.319   0.241    0.061
  Neutrophils               0.975            \<0.001          0.138              0.289   0.247    0.055
  Lymphocytes               0.251            0.051            −0.092             0.481   −0.001   0.993
  Monocytes                 0.672            \<0.001          0.022              0.869   −0.012   0.924
  Platelets                 0.190            0.142            0.083              0.524   −0.008   0.954
  CRP                       0.130            0.319            ---                ---     0.082    0.528

PSI: Pneumonia Severity Index; APACHE II: Acute Physiology and Chronic Health Evaluation II.
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